Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11009980 | 0.87 | CYP11B1 (0.47) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL6737213 | 0.87 | CYP11B1 (0.53) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL6737207 | 0.87 | CYP11B1 (0.53) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL11013190 | 0.87 | CYP11B1 (0.47) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL23839943 | 0.83 | CYP11B1 (0.48) | CYP11B1CYP11B2CA1CA2GSK3B | |
| SCHEMBL23832384 | 0.81 | GSK3B (0.48) | CYP11B1CYP11B2GSK3BALDH1A1P4HB | |
| SCHEMBL23832239 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL28936364 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL23832375 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL16110489 | 0.79 | CYP2C9 (0.50) | CYP11B1CYP11B2GSK3BKMT2ANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4121424-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121425-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605467-A | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-115551845-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115515948-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021188936-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188944-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | CYP11B1 436/4885CYP11B2 475/4885CA1 1102/4885 |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | HIF1AN, EGLN3, EGLN2 | CYP11B1 343/4885CYP11B2 362/4885CA1 1189/4885 |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | CYP11B1 424/4885CYP11B2 458/4885CA1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.